Thomas G Wiggans
CIK 1208907 · Chief Executive Officer · last filed 2026-08-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DERM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3290 WEST BAYSHORE ROAD
PALO ALTO, CA 94303
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JSPR | Director | — | $0.49 | — | $0 | 1 | 2026-08-04 |
| PCRX | Director | — | $36.39 | — | $0 | 1 | 2026-06-12 |
| Jasper Therapeutics, Inc. (JSPRW) Delisted | Director | 46,000 | $0.00 | $9 | $130.7K | 7 | 2025-09-24 |
| ANNX | Director | — | $3.71 | — | $0 | 5 | 2025-06-09 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | — | $32.48 | — | $0 | 5 | 2024-03-22 |
| PARDES BIOSCIENCES, INC. (PRDS) Delisted | Chief Executive Officer | 0 | $2.16 | $0 | $53.0K | 6 | 2023-08-31 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 4 | 2022-10-14 |
| DERM | CEO & Chairman of the Board | 233,506 | $5.01 | $1.17M | -$5.33M | 40 | 2019-08-19 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Director | 8,115 | — | — | -$2.07M | 19 | 2013-05-23 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 15,286 | — | — | -$80.9K | 13 | 2012-07-03 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | — | $0.18 | — | $0 | 4 | 2011-06-03 |
Recent Filings · Page 7 of 12
116 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-10-04 | DERM | Sell (S) | −11,000 | -$380.6K | EDGAR |
| 2016-09-02 | DERM | Sell (S) | −11,000 | -$347.9K | EDGAR |
| 2016-08-16 | DERM | Mixed | +1,872 | -$35.6K | EDGAR |
| 2016-08-03 | DERM | Mixed | −15,000 | -$365.1K | EDGAR |
| 2016-07-06 | DERM | Sell (S) | −11,000 | -$325.8K | EDGAR |
| 2016-06-03 | DERM | Sell (S) | −11,000 | -$347.3K | EDGAR |
| 2016-05-03 | DERM | Sell (S) | −9,000 | -$226.0K | EDGAR |
| 2016-04-05 | DERM | Sell (S) | −7,000 | -$144.8K | EDGAR |
| 2016-03-02 | DERM | Sell (S) | −7,000 | -$158.0K | EDGAR |
| 2016-02-09 | DERM | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.